NANOG

Researchers elucidate the biological pathways leading to cisplatin resistance in patients with cervical cancer. SEOUL, South Korea, July 21, 2023 /PRNewswire/ -- Cisplatin is a widely used chemotherapy drug for various types of cancers. However, frequent usage can lead to the development of drug resistance and neuropathic pain, eventually resulting in treatment failure. In a new study, researchers from South Korea investigated the underlying pathways contributing to this resistance and identified potential therapeutic targets that can be modulated to overcome this. By understanding and targeting these mechanisms, effective treatment strategies can be developed and implemented. Continue Reading The study reveals that the transcription factor NANOG activates the transient receptor potential vanilloid 1 (TRPV1)-causing neuropathic pain. TRPV1 further stimulates the EGFR signaling pathway, thus leading to cisplatin resistance. Cisplatin is a potent chemotherapeutic agent used to treat various cancers, including cervical cancer. But the continued use of cisplatin can lead to the development of cisplatin resistance and other side effects, like chemotherapy-induced neuropathic pain. Overcoming these issues is a critical concern in cervical cancer treatment. Now, in a new study, Prof. Tae Woo Kim from Korea University Medicine and his team have explored the pathways leading to cisplatin resistance. Their study was published online on 10 May 2023 in Nature Communications. The team analyzed the transcriptome of patients with cervical cancer who had undergone surgery and found that elevated epidermal growth factor receptor (EGFR) activity scores were associated with poor overall survival in cisplatin-treated patients. "EGFR is a protein involved in cell signaling and its dysregulation leads to uncontrolled cell growth and tumor formation. We conducted experiments on EGFR signaling using cervical cancer cell lines and observed that the cisplatin-resistant cell line exhibited hyperactivated EGFR signaling compared to the cisplatin-susceptible cells. This led us to conclude that hyperactive EGFR triggers resistance mechanisms, leading to decreased drug effectiveness in tumor cells," explains Prof. Kim. The team further identified NANOG, a transcription factor associated with resistance, metastasis, and stem cell-like properties in cancer cells, to be involved in the regulation of the EGFR pathway. They discovered that NANOG activates the transient receptor potential vanilloid 1 (TRPV1), which is responsible for causing neuropathic pain. TRPV1 further promotes a process called secretory autophagy, which leads epidermal growth factor (EGF) secretion. EGF, in turn, activates the EGFR signaling pathway, contributing to cisplatin resistance. "Most noteworthily, in our study, inhibiting TRPV1 using AMG9810, a potential pain-relieving agent, rendered the resistant tumors vulnerable to cisplatin," says Prof. Kim. This study serves as valuable proof-of-concept for TRPV1 as a therapeutic target to combat cisplatin resistance and neuropathic pain, thereby improving the outlook for patients with cervical cancer. Reference Title of original paper: TRPV1 inhibition overcomes cisplatin resistance by blocking autophagy mediated hyperactivation of EGFR signaling pathway Journal: Nature Communications DOI: About the Korea University Medicine Korea University (KU), located in Seoul, South Korea, is a leading university established in 1905, renowned for its academic excellence and contributions to higher education. Within KU, Korea University Medicine (KU Medicine) is a top-ranked medical institution, comprising campuses like Anam Hospital, Guro Hospital, Ansan Hospital, Cheongdam Goyeong Campus, and Jeongneung Mediscience Park. KU Medicine also has educational institutions affiliated to it, including the College of Medicine, Graduate School of Public Health, and Graduate School of Clinical Dentistry, driving remarkable advancements in medical treatment, education, research, and social contributions. Website: Media Contact: Gihyun Park +82 2 3407 4043 [email protected] SOURCE Korea University Medicine